# Research Idea Ranking

**Generated:** 2026-02-03T18:37:14.652033
**Model:** openai/gpt-5.2 (reasoning: high)
**Tokens:** 7391

---

### Rankings

**#1: State Insulin Copay Caps and Working-Age Diabetes Mortality (Redesigned)**
- **Score:** 74/100  
- **Strengths:** High policy salience and genuinely under-studied *hard* outcome (mortality), with a large number of treated states and a very long pre-period for diagnosing pre-trends. CDC WONDER is accessible and the staggered timing fits modern staggered DiD (e.g., Callaway–Sant’Anna).  
- **Concerns:** The outcome is only imperfectly targeted to the treated population (commercially insured insulin users), so estimated effects may be substantially diluted and biased toward null. COVID-era mortality shocks plus other contemporaneous insulin-related changes (manufacturer programs, state affordability initiatives, Medicare insulin cap for <65 disabled) can confound if not handled carefully.  
- **Novelty Assessment:** **Moderately high novelty.** Many papers on insulin affordability/caps and *utilization/spending/adherence* using claims; far fewer on downstream population mortality effects attributable to these caps, especially with modern staggered DiD design.  
- **DiD Assessment (mandatory 8 criteria):**
  - **Pre-treatment periods:** **Strong** (1999–2019 gives ~20 years pre for earliest effective dates)
  - **Selection into treatment:** **Marginal** (adoption plausibly correlated with unobserved health-policy preferences and baseline diabetes burden; must test for differential pre-trends and consider covariate-adjusted/event-study robustness)
  - **Comparison group:** **Strong** (many never-/not-yet-treated states; can further restrict to common support / region / baseline mortality quantiles)
  - **Treatment clusters:** **Strong** (≈25+ treated states)
  - **Concurrent policies:** **Marginal** (other insulin affordability actions and broader health-policy shifts; COVID is a major national shock with heterogeneous state severity)
  - **Outcome-Policy Alignment:** **Marginal** (mechanism is plausible—lower OOP insulin → higher adherence → fewer acute events/deaths—but death-certificate “diabetes” mortality is downstream and noisy relative to insulin rationing)
  - **Data-Outcome Timing:** **Marginal** (WONDER is calendar-year deaths; laws often effective Jan 1 but not always—mid-year effective dates create partial exposure unless you shift treatment to first full-exposure year or use exposure-weighted treatment)
  - **Outcome Dilution:** **Marginal** (policy affects commercially insured insulin users; outcome includes all payers and all diabetes deaths—likely only ~15–35% of the death outcome is “treated,” depending on state composition; needs bounding/targeted sub-outcomes)
- **Recommendation:** **PURSUE (conditional on: (i) verifying WONDER cell suppression doesn’t destroy the panel for small states/25–64; (ii) coding treatment as “first full calendar year exposed” or exposure-weighted; (iii) adding more insulin-proximal mortality sub-outcomes such as DKA/hyperglycemic crisis deaths, and/or type 1 diabetes mortality as a higher-treated-share endpoint; (iv) a pre-analysis plan for handling 2020–2021 and concurrent insulin policies).**

---

**#2: State Laws Requiring Mental Health Education in K-12 Schools and Youth Suicide Rates**
- **Score:** 62/100  
- **Strengths:** Timely and important policy question with enough treated states and free national outcome data; plausible to implement a modern staggered DiD with long pre-periods. If credible, this would be highly visible to education and public health policymakers.  
- **Concerns:** Endogeneity risk is meaningful: states may adopt in response to worsening youth mental health/suicide trends (violating parallel trends). The policy-to-outcome link is long and implementation is heterogeneous; plus the outcome is rare and may be noisy/suppressed in smaller states/younger ages, making inference fragile.  
- **Novelty Assessment:** **Moderate novelty.** Youth suicide is heavily studied, but *this specific* state mandate (mental health education requirements) on *suicide mortality* is less saturated than, say, firearm policies, antidepressants, or broad school mental-health staffing/programs.  
- **DiD Assessment (mandatory 8 criteria):**
  - **Pre-treatment periods:** **Strong** (likely 2000s–2015+ pre for 2016–2023 adoption window)
  - **Selection into treatment:** **Marginal** (credible risk states adopt because youth outcomes deteriorate; must show flat differential pre-trends and maybe use adoption predictors unrelated to prior suicide changes)
  - **Comparison group:** **Marginal** (adopting states may differ systematically in education governance, baseline mental health infrastructure, urbanization)
  - **Treatment clusters:** **Strong** (20+ treated states)
  - **Concurrent policies:** **Marginal** (overlapping youth mental-health initiatives, crisis response funding, school safety laws; COVID-era disruptions also interact strongly with youth mental health)
  - **Outcome-Policy Alignment:** **Marginal** (suicide is a downstream “hard” outcome; education mandates may shift knowledge/help-seeking more than mortality directly, and effects likely lag)
  - **Data-Outcome Timing:** **Marginal** (policy is implemented in school years; WONDER is calendar-year deaths—first “treated” calendar year may include only partial school exposure unless treatment is aligned to first full school-year and mapped to calendar timing)
  - **Outcome Dilution:** **Marginal** (your 10–24 outcome includes many not in K–12; even within 10–18, only enrolled students are treated; dilution worsens if older teens/young adults account for most suicides)
- **Recommendation:** **CONSIDER (conditional on: (i) shifting outcome to 10–18 or even 10–17 to increase treated share; (ii) carefully aligning treatment timing to first full school-year exposure; (iii) documenting and, if possible, coding implementation intensity; (iv) pre-trend and placebo tests with multiple alternative control groups / synthetic DiD variants).**

---

**#3: State Insulin Copay Caps and Diabetes-Related Emergency Department Visits**
- **Score:** 45/100  
- **Strengths:** Conceptually the cleanest “mechanism” outcome—DKA/hyperglycemic crises are tightly linked to insulin underuse, so outcome-policy alignment is better than mortality. If high-frequency ED data were available, timing alignment and power could be strong.  
- **Concerns:** Data access is the likely dealbreaker: HCUP SEDD is costly and state participation varies by year; CDC NSSP public-use coverage is incomplete and not consistently state-representative. Without a clearly accessible, consistent panel covering many states/years, the design cannot be executed as proposed.  
- **Novelty Assessment:** **Moderately high novelty.** Some work links affordability to acute complications, but state copay caps specifically → DKA ED visits is not an overworked question; novelty is not the problem here—data is.  
- **DiD Assessment (mandatory 8 criteria):**
  - **Pre-treatment periods:** **Strong** *in principle* (if you can assemble multiple pre years in the same states)
  - **Selection into treatment:** **Marginal** (same political/endogeneity concerns as Idea 1)
  - **Comparison group:** **Strong** (many potential control states if data exists broadly)
  - **Treatment clusters:** **Strong** (25+ treated states)
  - **Concurrent policies:** **Marginal** (other insulin affordability changes)
  - **Outcome-Policy Alignment:** **Strong** (DKA/hyperglycemic crisis ED visits are a direct consequence of insulin rationing)
  - **Data-Outcome Timing:** **Marginal** (depends on whether outcome is monthly/quarterly vs annual; high-frequency helps, but only if consistently available)
  - **Outcome Dilution:** **Marginal** (copay caps still only affect commercially insured; ED data includes all payers—though you could mitigate if payer type is available in HCUP)
- **Recommendation:** **SKIP (unless you first secure: (i) a multi-state, multi-year ED dataset with consistent coverage; and ideally (ii) payer-type identifiers to reduce dilution and sharpen interpretation).**

---

**#4: State Mandatory Sexual Harassment Training Laws and EEOC Charge Filing Rates**
- **Score:** 35/100  
- **Strengths:** A policy-relevant question with an ambiguous sign (training could increase reporting via awareness or decrease harassment), which is intellectually interesting.  
- **Concerns:** Treated cluster count is far below what you need for credible state-policy DiD inference, and the EEOC outcome series is not clearly available as a consistent downloadable state-by-year panel. Identification is also weak because adoption likely follows high-profile incidents or heightened enforcement climates, directly tied to outcome trends.  
- **Novelty Assessment:** **Moderate novelty**, but not enough to overcome fundamental identification/data problems; related literatures on harassment training and reporting exist, though often at the firm/program level rather than state mandates.  
- **DiD Assessment (mandatory 8 criteria):**
  - **Pre-treatment periods:** **Weak** (unclear if a clean, consistent multi-year state panel of charge counts/rates is available with enough pre for each adopting state)
  - **Selection into treatment:** **Weak** (high risk laws are adopted in response to changing harassment/reporting climate—very likely correlated with the outcome trend)
  - **Comparison group:** **Marginal** (non-mandate states may differ systematically in labor regulation and enforcement)
  - **Treatment clusters:** **Weak** (<10 comprehensive mandate states → inference fragile / essentially non-credible at state-policy level)
  - **Concurrent policies:** **Marginal** (simultaneous expansions in protected classes, enforcement funding, #MeToo-era institutional changes)
  - **Outcome-Policy Alignment:** **Marginal** (EEOC charges measure reporting/enforcement behavior, not harassment incidence; interpretation hinges on theory you cannot separately identify)
  - **Data-Outcome Timing:** **Marginal** (charges may be filed with lags; annual aggregation may mis-time exposure)
  - **Outcome Dilution:** **Marginal** (mandates often apply only to certain firm sizes/sectors; EEOC charges pool across all workers)
- **Recommendation:** **SKIP.**

---

### Summary

This is a mixed batch: one clearly actionable design (Idea 1) with real promise if you directly address dilution and timing, one plausible-but-risky DiD (Idea 4) where selection and timing/implementation heterogeneity are the main threats, and two ideas that are primarily blocked by feasibility (Idea 3) or weak DiD fundamentals (Idea 2). I would start with **Idea 1** immediately, while tightening treatment timing and adding more insulin-proximal mortality endpoints; **Idea 4** is the next-best only if you can convincingly demonstrate no differential pre-trends and improve outcome alignment (age band, timing to school-year exposure).